Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

Haemophilia

Volumn 15, Issue 4, 2009, Pages 869-880

  Recht, Michael ^a   Nemes, L ^b   Matysiak, M ^c   Manco Johnson, M ^d   Lusher, J ^e   Smith, M ^f   Mannucci, P ^g   Hay, C ^h   Abshire, T ⁱ   O'Brien, A ^j   Hayward, B ^j   Udata, C ^j   Roth, D A ^j   Arkin, S ^j  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b State Health Center   (Hungary)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF COLORADO   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j PFIZER INC   (United States)

more..

Author keywords

BDDrFVIII; Factor VIII; Haemophilia; Pharmacokinetics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASTHENIA; BAYES THEOREM; BIOEQUIVALENCE; BLEEDING; BLOOD CLOTTING TEST; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYST; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; ECCHYMOSIS; FEMALE; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPLENOMEGALY; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; BAYES THEOREM; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649855138     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02027.x     Document Type: Article

References (17)

1. Meeks SL, Josephson CD. Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates. Curr Opin Hematol 2006; 13: 457-61.
2. Kelley BD, Booth J, Tannatt M et al. Isolation of a peptide ligand for affinity purification of factor VIII using phage display. J Chromatogr A 2004; 1038: 121-30.
3. Kelley BD, Tannatt M, Magnusson R, Hagelberg S, Booth J. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII. Biotechnol Bioeng 2004; 87: 400-12.
4. Recht M, Abshire T, Lusher J et.al. Results of a single-dose, randomized, double-blind, 2-period crossover pharmacokinetic study of B-domain deleted recombinant FVIII (BDDrFVIII), current manufacturing process (ReFacto), and BDDrFVIII, albumin-free manufacturing process (ReFacto AF). Blood 2003: Poster Session 162-III; 102: 111.
5. Lee M, Morfini M, Schulman S, Ingerslev J. The design and analysis of pharmacokinetic studies of coagulation factors. Scientific and Standardization Committee Communication. ISTH 2001. Available at: http://www.isth.org/Publications/OfficialCommunications/Factor8and9/ Pharmacokinetic.aspx.
6. Di Paola J, Smith MP, Klamroth R et.al. ReFacto and Advate: A single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
7. U.S. Department of Health and Human Services. Guidance for Industry Statistical Approaches to Establishing Bioequivalence. 2001.
8. Kessler C, Gill J, White G et.al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: A randomized, three-way crossover study. Haemophilia 2005; 11: 84-91.
9. Courter S, Bedrosian C. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38 (2 Suppl 4): 44-51.
10. Tarantino MD, Collins PW, Hay CRM et.al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
11. Lee M, Roth D. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
12. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
13. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Clinical Investigation of Recombinant Factor VIII and IX Products. London, UK. CPMP/BPWG/1561/99; October 2000.
14. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-951.
15. Ayugoren-Pursun E, Scharrer I, Group GKS. A multicenter phamacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
16. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIIII-FS) in patients with hemophilia A: A long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
17. White GC, Courter S, Bray G, Lee M, Gomperts E. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.